IL218543A0 - Pyrimidine derivatives as protein tyrosine kinase 2 inhibitors - Google Patents
Pyrimidine derivatives as protein tyrosine kinase 2 inhibitorsInfo
- Publication number
- IL218543A0 IL218543A0 IL218543A IL21854312A IL218543A0 IL 218543 A0 IL218543 A0 IL 218543A0 IL 218543 A IL218543 A IL 218543A IL 21854312 A IL21854312 A IL 21854312A IL 218543 A0 IL218543 A0 IL 218543A0
- Authority
- IL
- Israel
- Prior art keywords
- inhibitors
- tyrosine kinase
- protein tyrosine
- pyrimidine derivatives
- pyrimidine
- Prior art date
Links
- 102000018691 Focal Adhesion Kinase 1 Human genes 0.000 title 1
- 108010091824 Focal Adhesion Kinase 1 Proteins 0.000 title 1
- 229940123371 Tyrosine kinase 2 inhibitor Drugs 0.000 title 1
- 229940083082 pyrimidine derivative acting on arteriolar smooth muscle Drugs 0.000 title 1
- 150000003230 pyrimidines Chemical class 0.000 title 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D239/00—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings
- C07D239/02—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings
- C07D239/24—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings having three or more double bonds between ring members or between ring members and non-ring members
- C07D239/28—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings having three or more double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, directly attached to ring carbon atoms
- C07D239/46—Two or more oxygen, sulphur or nitrogen atoms
- C07D239/47—One nitrogen atom and one oxygen or sulfur atom, e.g. cytosine
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D239/00—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings
- C07D239/70—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings condensed with carbocyclic rings or ring systems
- C07D239/72—Quinazolines; Hydrogenated quinazolines
- C07D239/78—Quinazolines; Hydrogenated quinazolines with hetero atoms directly attached in position 2
- C07D239/84—Nitrogen atoms
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
- A61K31/506—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim not condensed and containing further heterocyclic rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
- C07D401/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a chain containing hetero atoms as chain links
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
- C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
- C07D403/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings linked by a chain containing hetero atoms as chain links
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
- C07D417/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings
- C07D417/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings linked by a chain containing hetero atoms as chain links
Landscapes
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Health & Medical Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- General Health & Medical Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Medicinal Chemistry (AREA)
- Life Sciences & Earth Sciences (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- Immunology (AREA)
- Oncology (AREA)
- Rheumatology (AREA)
- Communicable Diseases (AREA)
- Pain & Pain Management (AREA)
- Epidemiology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Plural Heterocyclic Compounds (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
- Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
- Nitrogen Condensed Heterocyclic Rings (AREA)
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| EP09172026 | 2009-10-02 | ||
| EP10172460 | 2010-08-11 | ||
| PCT/EP2010/064628 WO2011039344A1 (en) | 2009-10-02 | 2010-10-01 | Pyrimidine derivatives as protein tyrosine kinase 2 inhibitors |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| IL218543A0 true IL218543A0 (en) | 2012-05-31 |
Family
ID=43048878
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| IL218543A IL218543A0 (en) | 2009-10-02 | 2012-03-08 | Pyrimidine derivatives as protein tyrosine kinase 2 inhibitors |
Country Status (25)
| Country | Link |
|---|---|
| US (1) | US8466155B2 (OSRAM) |
| EP (1) | EP2483249B1 (OSRAM) |
| JP (1) | JP5702390B2 (OSRAM) |
| KR (1) | KR20120092617A (OSRAM) |
| CN (1) | CN102695700A (OSRAM) |
| AP (1) | AP2012006166A0 (OSRAM) |
| AR (1) | AR078513A1 (OSRAM) |
| AU (1) | AU2010302648A1 (OSRAM) |
| BR (1) | BR112012007300A2 (OSRAM) |
| CA (1) | CA2775418A1 (OSRAM) |
| CL (1) | CL2012000825A1 (OSRAM) |
| EA (1) | EA201200552A1 (OSRAM) |
| EC (1) | ECSP12011830A (OSRAM) |
| IL (1) | IL218543A0 (OSRAM) |
| IN (1) | IN2012DN02714A (OSRAM) |
| MA (1) | MA33606B1 (OSRAM) |
| MX (1) | MX2012003101A (OSRAM) |
| NZ (1) | NZ598614A (OSRAM) |
| PE (1) | PE20121431A1 (OSRAM) |
| PH (1) | PH12012500527A1 (OSRAM) |
| TN (1) | TN2012000142A1 (OSRAM) |
| TW (1) | TW201124386A (OSRAM) |
| UY (1) | UY32916A (OSRAM) |
| WO (1) | WO2011039344A1 (OSRAM) |
| ZA (1) | ZA201201703B (OSRAM) |
Families Citing this family (30)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US20120244141A1 (en) | 2010-09-28 | 2012-09-27 | Boehringer Ingelheim International Gmbh | Stratification of cancer patients for susceptibility to therapy with PTK2 inhibitors |
| US8754114B2 (en) | 2010-12-22 | 2014-06-17 | Incyte Corporation | Substituted imidazopyridazines and benzimidazoles as inhibitors of FGFR3 |
| CN103534240B (zh) | 2011-02-17 | 2015-12-09 | 癌症疗法Crc私人有限公司 | 选择性fak抑制剂 |
| AU2012216893B2 (en) | 2011-02-17 | 2016-08-11 | Cancer Therapeutics Crc Pty Limited | FAK inhibitors |
| WO2013086260A2 (en) * | 2011-12-09 | 2013-06-13 | Oncomed Pharmaceuticals, Inc. | Combination therapy for treatment of cancer |
| WO2013146963A1 (ja) * | 2012-03-28 | 2013-10-03 | 武田薬品工業株式会社 | 複素環化合物 |
| RS61089B1 (sr) | 2012-06-13 | 2020-12-31 | Incyte Holdings Corp | Supstituisana triciklična jedinjenja kao inhibitori fgfr |
| WO2014026125A1 (en) | 2012-08-10 | 2014-02-13 | Incyte Corporation | Pyrazine derivatives as fgfr inhibitors |
| US9266892B2 (en) | 2012-12-19 | 2016-02-23 | Incyte Holdings Corporation | Fused pyrazoles as FGFR inhibitors |
| DK2986610T5 (en) | 2013-04-19 | 2018-12-10 | Incyte Holdings Corp | BICYCLIC HETEROCYCLES AS FGFR INHIBITORS |
| CA2949048A1 (en) * | 2013-05-22 | 2014-11-27 | The Regents Of The University Of California | Aurora kinase inhibitors |
| US10851105B2 (en) | 2014-10-22 | 2020-12-01 | Incyte Corporation | Bicyclic heterocycles as FGFR4 inhibitors |
| MA41551A (fr) | 2015-02-20 | 2017-12-26 | Incyte Corp | Hétérocycles bicycliques utilisés en tant qu'inhibiteurs de fgfr4 |
| WO2016134294A1 (en) | 2015-02-20 | 2016-08-25 | Incyte Corporation | Bicyclic heterocycles as fgfr4 inhibitors |
| SG11201706287PA (en) | 2015-02-20 | 2017-09-28 | Incyte Corp | Bicyclic heterocycles as fgfr inhibitors |
| AR111960A1 (es) | 2017-05-26 | 2019-09-04 | Incyte Corp | Formas cristalinas de un inhibidor de fgfr y procesos para su preparación |
| KR20210018264A (ko) | 2018-05-04 | 2021-02-17 | 인사이트 코포레이션 | Fgfr 억제제의 염 |
| WO2019213544A2 (en) | 2018-05-04 | 2019-11-07 | Incyte Corporation | Solid forms of an fgfr inhibitor and processes for preparing the same |
| US11628162B2 (en) | 2019-03-08 | 2023-04-18 | Incyte Corporation | Methods of treating cancer with an FGFR inhibitor |
| WO2021007269A1 (en) | 2019-07-09 | 2021-01-14 | Incyte Corporation | Bicyclic heterocycles as fgfr inhibitors |
| WO2021067374A1 (en) | 2019-10-01 | 2021-04-08 | Incyte Corporation | Bicyclic heterocycles as fgfr inhibitors |
| EP4045151A1 (en) | 2019-10-14 | 2022-08-24 | Incyte Corporation | Bicyclic heterocycles as fgfr inhibitors |
| US11566028B2 (en) | 2019-10-16 | 2023-01-31 | Incyte Corporation | Bicyclic heterocycles as FGFR inhibitors |
| IL293001A (en) | 2019-12-04 | 2022-07-01 | Incyte Corp | Derivatives of fgfr repressors |
| WO2021113479A1 (en) | 2019-12-04 | 2021-06-10 | Incyte Corporation | Tricyclic heterocycles as fgfr inhibitors |
| US12012409B2 (en) | 2020-01-15 | 2024-06-18 | Incyte Corporation | Bicyclic heterocycles as FGFR inhibitors |
| JP2024513575A (ja) | 2021-04-12 | 2024-03-26 | インサイト・コーポレイション | Ｆｇｆｒ阻害剤及びネクチン－４標的化剤を含む併用療法 |
| WO2022261160A1 (en) | 2021-06-09 | 2022-12-15 | Incyte Corporation | Tricyclic heterocycles as fgfr inhibitors |
| TW202313610A (zh) | 2021-06-09 | 2023-04-01 | 美商英塞特公司 | 作為ｆｇｆｒ抑制劑之三環雜環 |
| WO2023107705A1 (en) | 2021-12-10 | 2023-06-15 | Incyte Corporation | Bicyclic amines as cdk12 inhibitors |
Family Cites Families (18)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| GB0004887D0 (en) * | 2000-03-01 | 2000-04-19 | Astrazeneca Uk Ltd | Chemical compounds |
| RU2330024C2 (ru) | 2001-05-29 | 2008-07-27 | Шеринг Акциенгезельшафт | Ингибирующие cdk-киназы пиримидины, способ их получения и их применение в качестве лекарственных средств |
| EP1438053B1 (de) | 2001-10-17 | 2008-09-10 | Boehringer Ingelheim Pharma GmbH & Co.KG | Pyrimidinderivate, arzneimittel enthaltend diese verbindungen, deren verwendung und verfahren zu ihrer herstellung |
| WO2003076437A1 (de) * | 2002-03-11 | 2003-09-18 | Schering Aktiengesellschaft | Cdk inhibitorische 2-heteroaryl-pyrimidine, deren herstellung und verwendung als arzneimittel |
| AR042486A1 (es) | 2002-12-18 | 2005-06-22 | Glaxo Group Ltd | Compuesto de quinolina y naftiridina halosustituido en la posicion 3, procedimiento para preparar el compuesto, composicion farmaceutica que lo comprende y su uso para preparar dicha composicion . |
| JP4812763B2 (ja) | 2004-05-18 | 2011-11-09 | ライジェル ファーマシューティカルズ， インコーポレイテッド | シクロアルキル置換ピリミジンジアミン化合物およびそれらの用途 |
| WO2006034872A1 (de) * | 2004-09-29 | 2006-04-06 | Bayer Schering Pharma Aktiengesellschaft | Substituierte 2-anilinopyrimidine als zellzyklus -kinase oder rezeptortyrosin-kinase inhibitoren, deren herstellung und verwendung als arzneimittel |
| US20070032514A1 (en) * | 2005-07-01 | 2007-02-08 | Zahn Stephan K | 2,4-diamino-pyrimidines as aurora inhibitors |
| CA2634646C (en) | 2005-12-21 | 2012-04-10 | Pfizer Products Inc. | Pyrimidine derivatives for the treatment of abnormal cell growth |
| US8623887B2 (en) | 2006-05-15 | 2014-01-07 | Boehringer Ingelheim International Gmbh | Compounds |
| TW200808325A (en) * | 2006-07-06 | 2008-02-16 | Astrazeneca Ab | Novel compounds |
| GB0619343D0 (en) | 2006-09-30 | 2006-11-08 | Vernalis R&D Ltd | New chemical compounds |
| EP2109605B1 (en) * | 2006-12-22 | 2013-02-20 | Boehringer Ingelheim International GmbH | 2- [(phenylamino) -pyrimidin-4ylamin0] -cyclopentane carboxamide derivatives and related compounds as inhibitors of kinases of the cell cycle for the treatment of cancer |
| CA2684470C (en) | 2007-04-16 | 2016-02-09 | Hutchison Medipharma Enterprises Limited | Pyrimidine derivatives |
| TWI458721B (zh) | 2008-06-27 | 2014-11-01 | Celgene Avilomics Res Inc | 雜芳基化合物及其用途 |
| US8338439B2 (en) | 2008-06-27 | 2012-12-25 | Celgene Avilomics Research, Inc. | 2,4-disubstituted pyrimidines useful as kinase inhibitors |
| TW201024281A (en) | 2008-11-24 | 2010-07-01 | Boehringer Ingelheim Int | New compounds |
| KR101705158B1 (ko) | 2009-05-05 | 2017-02-09 | 다나-파버 캔서 인스티튜트 인크. | Ｅｇｆｒ 억제제 및 질환 치료방법 |
-
2010
- 2010-09-29 US US12/893,240 patent/US8466155B2/en active Active
- 2010-09-30 UY UY0001032916A patent/UY32916A/es not_active Application Discontinuation
- 2010-10-01 AR ARP100103594A patent/AR078513A1/es unknown
- 2010-10-01 MX MX2012003101A patent/MX2012003101A/es active IP Right Grant
- 2010-10-01 EA EA201200552A patent/EA201200552A1/ru unknown
- 2010-10-01 CN CN201080054924XA patent/CN102695700A/zh active Pending
- 2010-10-01 EP EP10759924.3A patent/EP2483249B1/en active Active
- 2010-10-01 IN IN2714DEN2012 patent/IN2012DN02714A/en unknown
- 2010-10-01 JP JP2012531442A patent/JP5702390B2/ja active Active
- 2010-10-01 AP AP2012006166A patent/AP2012006166A0/xx unknown
- 2010-10-01 NZ NZ598614A patent/NZ598614A/xx not_active IP Right Cessation
- 2010-10-01 AU AU2010302648A patent/AU2010302648A1/en not_active Abandoned
- 2010-10-01 PH PH1/2012/500527A patent/PH12012500527A1/en unknown
- 2010-10-01 TW TW099133534A patent/TW201124386A/zh unknown
- 2010-10-01 WO PCT/EP2010/064628 patent/WO2011039344A1/en not_active Ceased
- 2010-10-01 PE PE2012000420A patent/PE20121431A1/es not_active Application Discontinuation
- 2010-10-01 KR KR1020127011321A patent/KR20120092617A/ko not_active Withdrawn
- 2010-10-01 BR BR112012007300A patent/BR112012007300A2/pt not_active IP Right Cessation
- 2010-10-01 CA CA2775418A patent/CA2775418A1/en not_active Abandoned
-
2012
- 2012-03-08 IL IL218543A patent/IL218543A0/en unknown
- 2012-03-08 ZA ZA2012/01703A patent/ZA201201703B/en unknown
- 2012-03-26 MA MA34719A patent/MA33606B1/fr unknown
- 2012-03-29 TN TNP2012000142A patent/TN2012000142A1/en unknown
- 2012-04-02 CL CL2012000825A patent/CL2012000825A1/es unknown
- 2012-04-26 EC ECSP12011830 patent/ECSP12011830A/es unknown
Also Published As
| Publication number | Publication date |
|---|---|
| EA201200552A1 (ru) | 2013-03-29 |
| CA2775418A1 (en) | 2011-04-07 |
| AR078513A1 (es) | 2011-11-16 |
| NZ598614A (en) | 2013-08-30 |
| JP2013506636A (ja) | 2013-02-28 |
| MA33606B1 (fr) | 2012-09-01 |
| ECSP12011830A (es) | 2012-06-29 |
| PE20121431A1 (es) | 2012-11-10 |
| US20110237598A1 (en) | 2011-09-29 |
| IN2012DN02714A (OSRAM) | 2015-09-11 |
| TN2012000142A1 (en) | 2013-09-19 |
| PH12012500527A1 (en) | 2012-10-22 |
| EP2483249A1 (en) | 2012-08-08 |
| US8466155B2 (en) | 2013-06-18 |
| AP2012006166A0 (en) | 2012-04-30 |
| CL2012000825A1 (es) | 2012-08-24 |
| UY32916A (es) | 2011-04-29 |
| MX2012003101A (es) | 2012-04-11 |
| AU2010302648A1 (en) | 2012-04-05 |
| KR20120092617A (ko) | 2012-08-21 |
| EP2483249B1 (en) | 2015-12-23 |
| WO2011039344A1 (en) | 2011-04-07 |
| TW201124386A (en) | 2011-07-16 |
| JP5702390B2 (ja) | 2015-04-15 |
| BR112012007300A2 (pt) | 2017-11-07 |
| CN102695700A (zh) | 2012-09-26 |
| ZA201201703B (en) | 2014-05-28 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| IL218543A0 (en) | Pyrimidine derivatives as protein tyrosine kinase 2 inhibitors | |
| PL2610256T3 (pl) | Pochodne pirymidyny jako inhibitory kinaz białkowych | |
| HUS1900014I1 (hu) | Proteinkináz inhibitorok | |
| IL210124A0 (en) | Pyrimidine derivatives as kinase inhibitors | |
| PT2200436E (pt) | Pirimidinilaminas substituídas como inibidoras da proteína quinase | |
| ZA201004243B (en) | Benzofuropyrimidinones as protein kinase inhibitors | |
| PL2203449T3 (pl) | Heterocykliczne związki bicykliczne jako inhibitory białkowej kinazy tyrozynowej | |
| PT2197880E (pt) | Compostos heterocíclicos bicíclicos como inibidores da proteína tirosina cinase | |
| ZA201201978B (en) | Methods for preparing pyrimidine derivatives useful as protein kinase inhibitors | |
| ZA201001512B (en) | Inhibitors of protein tyrosine kinase activity | |
| PL2193133T3 (pl) | Imidazolotiadiazole do stosowania jako inhibitory kinazy białkowej | |
| ZA200909223B (en) | Pyrimidine derivatives useful as raf kinase inhibitors | |
| SI2252597T1 (sl) | Derivati pirazina in njihova uporaba kot inhibitorji protein kinaze | |
| IL207946A0 (en) | Inhibitors of protein tyrosine kinase activity | |
| IL210073A0 (en) | Protein kinase inhibitors | |
| PT2231642E (pt) | Pirimidinas como inibidores de quinase | |
| IL210069A0 (en) | Protein kinase inhibitors | |
| IL218790A0 (en) | Methods for preparing pyrimidine derivatives useful as protein kinase inhibitors | |
| EP2247185A4 (en) | INHIBITORS OF TYROSINE KINASE | |
| IL194491A0 (en) | Thiazolyldihydroindazole derivatives as protein kinase inhibitors | |
| HK1150829A (en) | Pyrimidine derivatives as kinase inhibitors | |
| GB0807642D0 (en) | IKK- serine-threonine protein kinase inhibitors |